Ranitidine and metoclopramide are routinely given intravenously before surgical procedures that involve spinal or general anesthesia. Recently, another institution contacted our institution to request stability data to support the practice of routinely mixing ranitidine 50 mg and metoclopramide 10 mg in a 50-mL minibag of normal saline (0.9% sodium chloride) for IV administration before cesarean section. Before receiving this request, we had been unaware of this practice and assumed that these medications were to be administered either concurrently via the Y-site connector or consecutively. However, when questioned about the administration of these 2 medications, the nursing staff unanimously reported that this practice had been followed for more than 5 years on our institution's maternity ward, as well as in the adult surgical daycare unit. The authors contacted other large maternity centres in the region and discovered only one other site that was mixing ranitidine and metoclopramide before administration.
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Commonly used compatibility references, including Trissel's handbook 1 and the King Guide, 2 were reviewed, a literature search was performed, and site-specific policies were reviewed for information about the specific combination of ranitidine 50 mg and metoclopramide 10 mg in 50 mL of normal saline; however, no stability or compatibility data were found. Ranitidine and metoclopramide are reported to be physically compatible at the Y-site connector and when combined in a syringe (without normal saline). 1, 2 In addition, in a study first published in 2010, Cabrera and others 3 evaluated the chemical and physical compatibility of an admixture containing 4 medications (ranitidine 150 mg, metoclopramide 50 mg, tramadol 500 mg, and ketorolac 150 mg in normal saline) stored at room temperature for 48 h, because this admixture was to be infused over 48 h for pain control. The authors found no change in colour, formation of precipitate, or phase separation. When the mean concentration of each drug was tested at 48 h, metoclopramide remained between 100% and 105% of its initial level and ranitidine between 99% and 102% of its initial level.
We conducted a small physical compatibility study by preparing a bag of ranitidine 50 mg (25 mg/mL; GlaxoSmith Kline, lot C618668, expiry August 2014) and metoclopramide 10 mg (10 mg/2 mL; Sandoz, lot CX8994, expiry October 2015) in 50 mL of normal saline (Baxter, lot W3E07C0, expiry May 2014). This admixture was left at room temperature (about 25°C) for 72 h. The bag was assessed at 1, 17, 26, 41, and 72 h; at each time point, there was no visible evidence of colour change, precipitate, or phase separation in the admixture. Although these results do not exclude the risk of incompatibility or changes in efficacy, this information does add to the clinical data at our site indicating that these 2 medications are physically compatible when combined in normal saline.
We would be interested to learn about others' experience with this drug combination, including further clinical or laboratory stability data for the administration of ranitidine and metoclopramide in normal saline.
Acting on Adherence: Better Sooner than Later
The famous saying of former US surgeon general C Everett Koop-"Drugs don't work in patients who don't take them" 1 -recalls a sine qua non principle of medication: adherence is the prerequisite of effectiveness. As medication experts practising pharmaceutical care, pharmacists are central to improving medication adherence. In the 2000s, medication non-adherence has been associated with an annual loss of $7 billion in Canada, 2 underscoring the need for pharmacy practitioners to take action, both to promote positive pharmacotherapy outcomes for the patient and to support the sustainability of the health care system. Pharmacist-led initiatives and research on adherence are increasing steadily across Canada, including the CPATCH project (Community Pharmacists Assisting in Total Cardiovascular Health; http://cpatch.usask.ca/cpatch/index.php), led by a group from the University of Saskatchewan and the Royal University Hospital, 3 and the Mouvement pour l'adhésion au traitement, led by the Université Laval (www.adhesionauxtraitements.org/).
There are several determinants of adherence, many of which pharmacists can influence, notably by educating patients about the effects of medications on health outcomes and quality of life and by dispelling myths and fears. However, adherence is also tied to care at the various levels of the health care system (i.e., across the continuum of care). A patient's transition from the hospital to the community or a long-term care home (and vice versa) represents a sensitive moment, where slip-ups may occur, breaking seamless and optimal care. Given that hospitals usually deal with complex situations in which patients may be started on multiple long-term medications simultaneously, the work of hospital pharmacists could be a critical reference point where adherence can first be tackled. Developing this role would require several elements, notably, creating an environment that offers opportunities for increasing pharmacists' expertise in complex medication therapy (i.e., specialization) and increasing their involvement in medication counselling at the hospital; studying the hospital's selfmedication program to better support the role of pharmacists within an expanded interdisciplinary environment; and/or facilitating collaboration between hospital and community pharmacists (e.g., through better communication systems). Additionally, it would be beneficial to increase initiatives and research or pilot projects on adherence (especially those involving partnership between the hospital and the community) to identify gaps in practice along the continuum of care. An important target group in these studies could be patients with heart disease, since these patients are usually taking multiple medications to reduce morbidity and mortality 4 and cardiovascular diseases represent one of the most important causes of hospital admission and death in Canada. 4, 5 Currently, many patients get "lost" in the transition from hospital to community and vice versa (through fragmentation of care). This situation challenges us to ensure the implementation and maintenance of adherence but also begs for meaningful changes in the system to meet patients' needs and expectations and to increase collaboration among health care professionals at the different levels of care. Such change can be favoured by research and pilot projects in seamless care, an area that remains poorly explored. Data presented by the Web of Knowledge indicate that, although medication adherence has been gaining importance since 2007 in terms of the number of publications (Fig. 1) , only 4 of 20 818 articles published between 2007 and 2012 focused on seamless care and adherence (Fig. 2) . 6 At the same time, the first report of the Health Care Innovation Working Group underlined "that [Canadian] patients and their families are rightfully demanding timely care that is seamless." 7 Drugs represent a large proportion of our health care system's expenditures, growing by about 6% every 10 years. 8 With this growth, it becomes critical to improve achievement of desired outcomes. 8 One solution is to emphasize adherence as a third element of the medication triad, alongside efficacy and safety. As pharmacy practice moves toward patient-centred care, medication adherence becomes another way for hospital and community pharmacists to work together as they watch over the life and health of their patients. 
